Wolters Kluwer Launches CCH iFirm Personal Tax and CCH iFirm Accounts Production for U.K. Tax and Accounting Professionals
24.4.2025 10:00:00 EEST | Business Wire | Press release
Wolters Kluwer Tax and Accounting (TAA) today announced the launch of CCH iFirm Personal Tax and CCH iFirm Accounts Production within its award-winning cloud-based practice management and compliance software platform CCH iFirm® for U.K. professionals. These enhancements deliver seamless, integrated platforms that enhance efficiency, reduce errors, ensure compliance and a more efficient workflow for tax and accounting professionals.
Bas Kniphorst, Executive Vice President and Managing Director, Wolters Kluwer TAA Europe said: “These cloud solution modules represent a significant milestone in our commitment to innovation and quality. By providing cutting-edge tools that meet the evolving demands of the tax and accounting industry, we are strengthening our position as a leader in cloud accounting solutions. This not only enhances our product portfolio but also drives growth and reinforces our dedication to delivering exceptional value to our clients. We are confident these launches will empower professionals to focus on high-value tasks and deliver exceptional service.”
Redefining Tax Return Processing
CCH iFirm Personal Tax simplifies and streamlines the tax return process with fully scalable, forward-thinking technology. Since it’s cloud-based, there’s no need for manual updates or separate upgrades. It integrates data across the CCH iFirm product suite, enabling quick and efficient job completion.
Key benefits include:
- Quick and accurate tax return filing with an intuitive errors and exceptions panel
- Enhanced efficiency through customizable workflow templates
- Cloud-based scalability for real-time data access, eliminating manual rekeying and reducing errors
The Future of Cloud-Based Compliance
CCH iFirm Accounts Production revolutionizes accounts production with a cloud-based system designed for accuracy, compliance, and enabling quick, error-free, and risk-reduced processes. It integrates compliance workflows for sole traders, partnerships, and limited companies (FRS 105), freeing up time for high-value tasks and enhancing client offerings.
Key benefits include:
- Customizable final accounts for tailored financial statements
- Automated risk reduction through validation alerts
- Seamless data migration with built-in tools
The launch of these new cloud-based modules follows the launch of CCH iFirm AML in March 2024, which was independently recognized by the 2024 Accountancy Awards and won the Innovative Technology award category. Additionally, CCH iFirm AML was selected as a 2024 Stratus Award for Cloud Computing winner.
To learn more about CCH iFirm please visit https://www.wolterskluwer.com/en-gb/solutions/cch-ifirm-uk.
# # #
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com and follow us on LinkedIn, Facebook, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424611628/en/
Contacts
Media Contacts
Shannon Wherry
Associate Director, External Communications
Wolters Kluwer Tax & Accounting
Office: +1 972-209-2767
shannon.wherry@wolterskluwer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom